Quince Therapeutics Historical PE Ratio image   This QNCX PE ratio history page last updated 3/27/2024
Quince Therapeutics Historical PE Ratio Chart
PeriodPriceEarningsAnnualizedPE
Q3 2023
11/14/2023
0.90-0.15-0.60NA
Q2 2023
8/4/2023
1.21-0.14-0.56NA
Q1 2023
5/15/2023
1.54-0.34-1.36NA
Q4 2022
3/15/2023
0.85-0.13-0.52NA
Q3 2022
11/9/2022
0.74-0.22-0.88NA
Q2 2022
8/9/2022
2.14-0.51-2.04NA
Q1 2022
5/10/2022
3.72-0.72-2.88NA
Q4 2021
3/1/2022
4.41-0.78-3.12NA
Q3 2021
10/29/2021
13.20-0.73-2.92NA
Q2 2021
8/6/2021
67.14-0.74-2.96NA
Q1 2021
5/6/2021
36.68-0.78-3.12NA
Q4 2020
3/2/2021
36.41-0.69-2.76NA
Q3 2020
11/12/2020
47.47-0.73-2.92NA
Q2 2020
8/17/2020
45.15-0.60-2.40NA
Q1 2020
5/12/2020
45.78-0.61-2.44NA
Q4 2019
3/17/2020
36.05-0.46-1.84NA
Q3 2019
11/12/2019
22.67-0.37-1.48NA
Q2 2019
8/9/2019
27.69-0.57-2.28NA
Q3 2013
11/7/2013
9.460.461.845.1
Q2 2013
8/6/2013
8.990.331.326.8
Q1 2013
5/9/2013
8.690.240.969.1
Q4 2012
3/14/2013
7.020.220.888.0
Q3 2012
11/6/2012
4.85-0.17-0.68NA
Q2 2012
8/9/2012
7.130.110.4416.2
Quince Therapeutics PE History Chart
PeriodPriceEarningsTTMPE
Q3 2023
11/14/2023
0.90-0.15-0.76NA
Q2 2023
8/4/2023
1.21-0.14-0.83NA
Q1 2023
5/15/2023
1.54-0.34-1.20NA
Q4 2022
3/15/2023
0.85-0.13-1.58NA
Q3 2022
11/9/2022
0.74-0.22-2.23NA
Q2 2022
8/9/2022
2.14-0.51-2.74NA
Q1 2022
5/10/2022
3.72-0.72-2.97NA
Q4 2021
3/1/2022
4.41-0.78-3.03NA
Q3 2021
10/29/2021
13.20-0.73-2.94NA
Q2 2021
8/6/2021
67.14-0.74-2.94NA
Q1 2021
5/6/2021
36.68-0.78-2.80NA
Q4 2020
3/2/2021
36.41-0.69-2.63NA
Q3 2020
11/12/2020
47.47-0.73-2.40NA
Q2 2020
8/17/2020
45.15-0.60-2.04NA
Q1 2020
5/12/2020
45.78-0.61-2.01NA
Q4 2019
3/17/2020
36.05-0.46-0.94NA
Q3 2019
11/12/2019
22.67-0.37-0.15NA
Q2 2019
8/9/2019
27.69-0.570.4660.2
Q3 2013
11/7/2013
9.460.461.257.6
Q2 2013
8/6/2013
8.990.330.6214.5
Q1 2013
5/9/2013
8.690.240.4021.7
Q4 2012
3/14/2013
7.020.22NANA
Q3 2012
11/6/2012
4.85-0.17NANA
Q2 2012
8/9/2012
7.130.11NANA
Quotes delayed 20 minutes

Email EnvelopeFree QNCX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quince Therapeutics (QNCX) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

QTRX PE Ratio History
RAIN PE Ratio History
RANI PE Ratio History
RAPT PE Ratio History
RARE PE Ratio History
RBOT PE Ratio History
RCEL PE Ratio History
RCKT PE Ratio History
RCUS PE Ratio History
RDNT PE Ratio History
How should the QNCX historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Quince Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this QNCX Historical PE Ratio page.

What is the average historical PE for QNCX based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The QNCX historical PE ratio using the annualized quarterly earnings method works out to 9.0.

What is the average historical PE for QNCX based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The QNCX historical PE ratio using the TTM earnings method works out to 26.0.

On this page we presented the Quince Therapeutics Historical PE Ratio information for Quince Therapeutics' stock. The average QNCX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 9.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average QNCX historical PE based on this TTM earnings result method is 26.0. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this QNCX historical PE result, against the recent PE: when this page was posted on 3/26/2024, the most recent closing price for QNCX had been 1.13, and the most recent quarterly earnings result, annualized, was 1.84. Meanwhile, the most recent TTM earnings summed to 0.46. From these numbers, we calculate the recent QNCX PE on 3/26/2024 based on annualized quarterly EPS was 0.6. Based on QNCX's history, that recent PE is low relative to the historical average, with the recent PE 93.3% lower than the historical average PE across our data set for Quince Therapeutics. Looking at the recent QNCX PE on 3/26/2024 based on TTM EPS, we calculate the ratio at 2.5. Based on QNCX's history, that recent PE is low relative to the historical average, with the recent PE 90.4% lower than the average PE across our Quince Therapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on QNCX or any other given stock, valuation analysis for QNCX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Quince Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for QNCX. Thanks for visiting, and the next time you need to research QNCX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: CCK Dividend Growth Rate, Top Ten Hedge Funds Holding SCZ, ADS shares outstanding history.

 

Quince Therapeutics Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.